COUR Pharma, a clinical-stage biotechnology company focused on reprogramming the immune system to restore health in people with autoimmune diseases, has closed a $50.0M Series b funding round.
The financing, with participation from Lumira Ventures, Roche Venture Fund, and Sanofi, will advance COUR's proprietary nanoparticle (CNP) platform. This technology develops first-in-class disease-modifying therapies that target the root cause of conditions like type 1 diabetes, primary biliary cholangitis, and celiac disease, without suppressing normal immune system function.
